The present study has shown that the novel anticancer agent, BP-C1, is significantly reduced cell viability of human breast cancer cells through induction of apoptosis via activation of caspase 8 and caspase 9, increasing the expression of pro-apoptotic genes and reducing the expression of apoptotic inhibitory genes . Here, CASP9 is linked to breast carcinoma.